NPC
9
1
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer
Pembrolizumab + MRGOO3 as Neoadjuvant in NPC
Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC
IMRT vs 2DRT for NPC Patients
Plasma EBV DNA Monitoring in Post-treatment NPC Patients
Phase IIa Dose-Expansion and Biomarker Study of OPB-111077